Latest / Decera Clinical Education Oncology Podcast
Changing the Paradigm in HER2-Positive Early Breast Cancer
New data and broad indications for trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings.
Presenters:
Sara A. Hurvitz, MD, FACP
Professor of Medicine
Smith Family Endowed Chair in Women’s Health
Senior Vice President, Clinical Research Division
Fred Hutch Cancer Center
Head, Division of Hematology/Oncology, Department of Medicine
University of Washington School of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.